Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.
Amneal Pharmaceuticals, Inc. reports developments across a diversified pharmaceutical business built around Affordable Medicines, Specialty and AvKARE. Its updates commonly cover U.S. launches of complex generics, injectables, biosimilars and other affordable medicines, including respiratory inhalation and ophthalmic products, as well as branded specialty treatments in neurology and endocrinology.
News about AMRX also includes clinical and regulatory disclosures for products such as CREXONT for Parkinson’s disease, financial results, capital-structure updates, material agreements and governance matters. AvKARE-related updates center on distribution of pharmaceuticals and medical products to U.S. federal, retail and institutional customers.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will announce its first quarter 2022 financial results on May 4, 2022, before the market opens. A conference call and live webcast with investors will occur at 8:30 a.m. Eastern Time the same day. Investors can access the financial results and the webcast on the company’s Investor Relations website. For those wishing to join the call, U.S. participants can dial (844) 200-6205 and international callers can use (929) 526-1599, with access code 874223.
Amneal Pharmaceuticals (NYSE: AMRX) has announced the presentation of topline results from its pivotal Phase 3 RISE-PD trial for IPX-203, a novel CD/LD formulation for Parkinson's disease, at the American Academy of Neurology Annual Meeting from April 2-7, 2022, in Seattle, WA. The trial demonstrated significant improvement in "Good On" time per dose, indicating potential benefits in symptom control. A New Drug Application is planned for submission in Q2 2022. The study involved 506 patients across 105 sites in the U.S. and Europe, showcasing Amneal's commitment to advancing Parkinson's treatments.
Amneal Pharmaceuticals (NYSE: AMRX) has secured a sub-license from the Medicines Patent Pool (MPP) to manufacture and commercialize a generic version of nirmatrelvir, co-packaged with ritonavir, in 95 low- and middle-income countries. This oral protease inhibitor, marketed as PAXLOVIDTM by Pfizer, has shown an 89% reduction in COVID-19-related hospitalizations. Amneal aims to produce nirmatrelvir in India and utilize its FDA-approved generic ritonavir from both India and the U.S., potentially delivering hundreds of millions of doses to impacted populations.
Amneal Pharmaceuticals (NYSE: AMRX) reported Q4 2021 net revenue of $537 million, a 5% increase from Q4 2020, despite a GAAP net loss of $6 million. Full year net revenue reached $2.1 billion, up 5% year-over-year, with a GAAP net income of $11 million. Adjusted figures showed significant growth, including Adjusted Net Income of $258 million and Adjusted EBITDA of $538 million for 2021. For 2022, the company expects net revenue between $2.15 billion and $2.25 billion and adjusted EBITDA of $540 million to $560 million.
Amneal Pharmaceuticals (NYSE: AMRX) received FDA approval for RELEUKO™, a biosimilar to Neupogen®, targeting neutropenia treatment. Developed with Kashiv Biosciences, this marks Amneal's first biosimilar launch, anticipated in Q3 2022. The U.S. market for filgrastim saw annual sales of $407 million as of December 2021, with biosimilar sales at $275 million. Amneal plans additional biosimilars for launch later in 2022, emphasizing their commitment to affordable medicine access.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has received FDA approval for four generic injectable products: Dexamethasone, Azacitidine, Carboprost, and Atropine. This strategic move aims to bolster Amneal's position in the U.S. institutional injectables market, addressing drug shortages of Dexamethasone and Azacitidine. Collectively, the annual sales of these products were approximately $184 million for the year ending December 2021. Amneal plans to expand its injectables portfolio, targeting over 40 launches by 2025, focusing on complex therapeutic areas.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced it will release its fourth quarter and full year 2021 financial results on March 2, 2022, before market open. A conference call will follow at 8:30 a.m. Eastern Time on the same day, accessible via the Investor Relations section of the Company’s website. Investors can dial (844) 200-6205 in the U.S. or (929) 526-1599 internationally to join the call. A replay will be available for seven days after the call. Amneal is a fully-integrated essential medicines company, focusing on generics and specialty pharmaceuticals.
Amneal Pharmaceuticals (NYSE: AMRX) has announced the acquisition of Saol Therapeutics' Baclofen franchise, which includes Lioresal and LYVISPAH, for approximately $83.5 million. This move expands Amneal's neurology portfolio and is expected to generate $40-$50 million in annual net revenues by 2025. The acquisition will enhance Amneal's commercial capabilities ahead of its entry into the biosimilar market, with anticipated positive impacts on adjusted EBITDA and earnings per share for 2022.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced that Co-CEO Chirag Patel will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 11:15 AM ET. The event will be accessible via a live webcast through the Company’s Investor Relations website, with a replay available for 30 days post-event. Amneal is focused on developing, manufacturing, and distributing generic and specialty pharmaceuticals, with a broad product portfolio across various therapeutic areas. The Company's growth strategy includes expanding its offerings, particularly in injectables and biosimilars.
Amneal Pharmaceuticals (NYSE: AMRX) has received FDA approval for its generic ophthalmic product, difluprednate ophthalmic emulsion 0.05%, a substitute for Durezol®, used to treat pain and inflammation from ocular surgery. This product marks a strategic shift towards more complex offerings in Amneal's portfolio. The annual sales for Durezol® and generics stand at approximately $103 million as of September 2021. However, potential side effects include increased risks of cataracts and glaucoma.